Company: RDPTF
Filing Date: 2025-09-18
Form Type: 20-F
Source: 0001213900-25-088699
Chunk: 85

Company: Radiopharm Theranostics Ltd
Filing Date: 2025-09-18
Form: 20-F
Item: Item 3
Chunk 85
---
 in fiscal 2024 to A$27,515,194 in fiscal 2025, due to an increase in expenses regarding NanoMab (from A$6,501,174
to A$7,185,000), R& D Venture (from A$3,931,541 to A$5,989,964), Pivalate - Imperial (from A$3,962,355 to A$5,184,136), huPSA
Anti-body (Diaprost) (from A$298,312 to A$2,925,445), AVB6 Integrin (from A$993,645 to A$1,876,983), consulting fees for research and
development (from A$929,229 to A$930,292) and other research and development expenses (from A$89,450 to A$171,605), partially offset by
decreases in expenses regarding amortization (from A$3,118,752 to A$2,588,306), impairment (from A$1,478,892 to A$0), NeoIndicate (from
A$529,424 to A$437,400), and UCLA collaboration expense (from A$1,253,493 to A$226,063).

Share based payments

Share-based payments expense
decreased from A$2,640,178 in fiscal 2024 to A$1,895,348 in fiscal 2025, due to a decrease in the expense recorded for options issued
in the current fiscal.

Finance expenses

Finance expenses decreased
from a loss of A$642,888 in fiscal 2024 to A$65,300 in fiscal 2025, as the financing agreement with Lind Global was terminated at the
start of the fiscal year.

Income tax expense

Income tax expense increased
from A$96,364 in fiscal 2024 to A$103,292 in fiscal 2025, due to the recognition of tax payable in Radiopharm (USA) Inc.

Exchange differences on translation of foreign operations

Exchange differences on translation
of foreign operations increased from A$202,956 in fiscal 2024 to A$464,034 in fiscal 2025, due to the fluctuation in foreign exchange
rates.

Total comprehensive loss

Total comprehensive loss decreased
A$9.9 million from A$47.7 million in fiscal 2024 to A$37.9 million in fiscal 2025, principally